XVIVO Stock Overview
A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Xvivo Perfusion AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 451.50 |
52 Week High | SEK 547.00 |
52 Week Low | SEK 252.50 |
Beta | 2.13 |
11 Month Change | -7.48% |
3 Month Change | -15.29% |
1 Year Change | 70.70% |
33 Year Change | 64.48% |
5 Year Change | 165.59% |
Change since IPO | 2,276.32% |
Recent News & Updates
Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 04Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 27Recent updates
Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 04Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 27With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For
Oct 25Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?
Aug 03Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Apr 25There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital
Apr 11Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates
Feb 05We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings
Feb 01Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jan 28Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled
Aug 24Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching
Jul 17Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?
Jun 16Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital
Apr 19Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?
Mar 23With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case
Mar 07When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?
Feb 13Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital
Dec 14Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?
Nov 17Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively
Aug 20Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are
Jul 21Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital
Mar 30At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?
Feb 18A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)
Jan 30Shareholder Returns
XVIVO | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | -0.8% | -5.8% | -2.4% |
1Y | 70.7% | -7.8% | 10.9% |
Return vs Industry: XVIVO exceeded the Swedish Medical Equipment industry which returned -7.8% over the past year.
Return vs Market: XVIVO exceeded the Swedish Market which returned 10.9% over the past year.
Price Volatility
XVIVO volatility | |
---|---|
XVIVO Average Weekly Movement | 4.6% |
Medical Equipment Industry Average Movement | 7.3% |
Market Average Movement | 5.5% |
10% most volatile stocks in SE Market | 11.2% |
10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: XVIVO has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: XVIVO's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 161 | Christoffer Rosenblad | www.xvivogroup.com |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.
Xvivo Perfusion AB (publ) Fundamentals Summary
XVIVO fundamental statistics | |
---|---|
Market cap | SEK 14.22b |
Earnings (TTM) | SEK 204.27m |
Revenue (TTM) | SEK 750.59m |
69.6x
P/E Ratio18.9x
P/S RatioIs XVIVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XVIVO income statement (TTM) | |
---|---|
Revenue | SEK 750.59m |
Cost of Revenue | SEK 192.08m |
Gross Profit | SEK 558.52m |
Other Expenses | SEK 354.25m |
Earnings | SEK 204.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 28, 2025
Earnings per share (EPS) | 6.48 |
Gross Margin | 74.41% |
Net Profit Margin | 27.21% |
Debt/Equity Ratio | 0% |
How did XVIVO perform over the long term?
See historical performance and comparison